Novel fgfr3 fusion

A kit for detecting a fusion gene composed of an FGFR3 gene and a TACC3 gene, which comprises a sense primer and an antisense primer designed to be able to specifically amplify a polynucleotide encoding the following polypeptide:

• A polypeptide which has tumorigenicity and comprises an amino acid sequence having 90% or more identity to the amino acid sequence represented by amino acid numbers 461 to 947 of SEQ ID NO:
• 2, amino acid numbers 461 to 982 of SEQ ID NO:
• 4, amino acid numbers 461 to 996 of SEQ ID NO:
• 6, amino acid numbers 461 to 1043 of SEQ ID NO:
• 26, or amino acid numbers 461 to 1040 of SEQ ID NO:
• 28.

A primer set for detecting a fusion gene composed of an FGFR3 gene and a TACC3 gene which is selected from a group consisting of the following a) to e):

• a) A primer set comprising an antisense primer consisting of nucleic acid molecules hybridized with a polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO:
• 1 under stringent conditions and a sense primer consisting of nucleic acid molecules hybridized with a complementary strand of the polynucleotide under stringent conditions,
• b) A primer set comprising an antisense primer consisting of nucleic acid molecules hybridized with a polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO:
• 3 under stringent conditions and a sense primer consisting of nucleic acid molecules hybridized with a complementary strand of the polynucleotide under stringent conditions,
• c) A primer set comprising an antisense primer consisting of nucleic acid molecules hybridized with a polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO:
• 5 under stringent conditions and a sense primer consisting of nucleic acid molecules hybridized with a complementary strand of the polynucleotide under stringent conditions,
• d) A primer set comprising an antisense primer consisting of nucleic acid molecules hybridized with a polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO:
• 25 under stringent conditions and a sense primer consisting of nucleic acid molecules hybridized with a complementary strand of the polynucleotide under stringent conditions, and
• e) A primer set comprising an antisense primer consisting of nucleic acid molecules hybridized with a polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO:
• 27 under stringent conditions and a sense primer consisting of nucleic acid molecules hybridized with a complementary strand of the polynucleotide under stringent conditions.

A primer set of:

• a sense primer consisting of an oligonucleotide of at least any consecutive 16 bases between nucleotide positions 1 and 2280 of SEQ ID NO:
• 1;
• and
• an antisense primer consisting of an oligonucleotide complementary to an oligonucleotide of at least any consecutive 16 bases between nucleotide positions 2281 to 2856 of SEQ ID NO:
• 1.

A primer set of:

• a sense primer consisting of an oligonucleotide of at least any consecutive 16 bases between nucleotide positions 1 and 2280 of SEQ ID NO:
• 3;
• and
• an antisense primer consisting of an oligonucleotide complementary to an oligonucleotide of at least any consecutive 16 bases between nucleotide positions 2281 and 2961 of SEQ ID NO:
• 3.

A primer set of:

• a sense primer consisting of an oligonucleotide of at least any consecutive 16 bases between nucleotide positions 1 and 2368 of SEQ ID NO:
• 5;
• and
• an antisense primer consisting of an oligonucleotide complementary to an oligonucleotide of at least any consecutive 16 bases between nucleotide positions 2369 and 3003 of SEQ ID NO:
• 5.

A primer set of:

• a sense primer consisting of an oligonucleotide of at least any consecutive 16 bases between nucleotide positions 1 and 2242 of SEQ ID NO:
• 25;
• and
• an antisense primer consisting of an oligonucleotide complementary to an oligonucleotide of at least any consecutive 16 bases between nucleotide positions 2243 and 3144 of SEQ ID NO:
• 25.

A primer set of:

• a sense primer consisting of an oligonucleotide of at least any consecutive 16 bases between nucleotide positions 1 and 2233 of SEQ ID NO:
• 27;
• and
• an antisense primer consisting of an oligonucleotide complementary to an oligonucleotide consisting of at least any consecutive 16 bases between nucleotide positions 2234 and 3135 of SEQ ID NO:
• 27.

Probe sets for detecting a fusion gene composed of an FGFR3 gene and a TACC3 gene which is selected from a group consisting of the following a) to c).

• a) Probe sets comprising multiple kinds of probe sets consisting of probe pairs which are adjacent to each other and comprise oligonucleotides complementary to at least any consecutive 16 bases between nucleotide positions 1 and 2280 of SEQ ID NO:
• 1, and multiple kinds of probe sets consisting of probe pairs which are adjacent to each other and comprise oligonucleotides complementary to at least any consecutive 16 bases between nucleotide positions 2281 and 2856 of SEQ ID NO:
• 1
• b) Probe sets comprising multiple kinds of probe sets consisting of probe pairs which are adjacent to each other and comprise oligonucleotides complementary to at least any consecutive 16 bases between nucleotide positions 1 and 2280 of SEQ ID NO:
• 3, and multiple kinds of probe sets consisting of probe pairs which are adjacent to each other and comprise oligonucleotides complementary to at least any consecutive 16 bases between nucleotide positions 2281 and 2961 of SEQ ID NO:
• 3
• c) Probe sets comprising multiple probe sets consisting of probe pairs which are adjacent to each other and comprise oligonucleotides complementary to at least any consecutive 16 bases between nucleotide positions 1 and 2368 of SEQ ID NO:
• 5, and multiple probe sets consisting of probe pairs which are adjacent to each other and comprise oligonucleotides complementary to at least any consecutive 16 bases between nucleotide positions 2369 and 3003 of SEQ ID NO:
• 5

A pharmaceutical composition for treating cancer which comprises a substance inhibiting the following polypeptide and is positive for either a fusion gene composed of an FGFR3 gene and a TACC3 gene or a fusion protein composed of FGFR3 and TACC3:

• A polypeptide which has tumorigenicity and comprises an amino acid sequence having 90% or more identity to the amino acid sequence represented by amino acid numbers 461 to 947 of SEQ ID NO:
• 2, amino acid numbers 461 to 982 of SEQ ID NO:
• 4, or amino acid numbers 461 to 996 of SEQ ID NO:
• 6.

Use of a substance inhibiting the following polypeptide for the manufacture of a pharmaceutical composition for treating cancer which is positive for either a fusion gene composed of an FGFR3 gene and a TACC3 gene or a fusion protein composed of FGFR3 and TACC3:

• A polypeptide which has tumorigenicity and comprises an amino acid sequence having 90% or more identity to the amino acid sequence represented by amino acid numbers 461 to 947 of SEQ ID NO:
• 2, amino acid numbers 461 to 982 of SEQ ID NO:
• 4, or amino acid numbers 461 to 996 of SEQ ID NO:
• 6.

Use of a substance inhibiting the following polypeptide for treating cancer which is positive for either a fusion gene composed of an FGFR3 gene and a TACC3 gene or a fusion protein composed of FGFR3 and TACC3:

• A polypeptide which has tumorigenicity and comprises an amino acid sequence having 90% or more identity to the amino acid sequence represented by amino acid numbers 461 to 947 of SEQ ID NO:
• 2, amino acid numbers 461 to 982 of SEQ ID NO:
• 4, or amino acid numbers 461 to 996 of SEQ ID NO:
• 6.

A substance inhibiting the following polypeptide for treating cancer which is positive for either a fusion gene composed of an FGFR3 gene and a TACC3 gene or a fusion protein composed of FGFR3 and TACC3,

• A polypeptide which has tumorigenicity and comprises an amino acid sequence having 90% or more identity to the amino acid sequence represented by amino acid numbers 461 to 947 of SEQ ID NO:
• 2, amino acid numbers 461 to 982 of SEQ ID NO:
• 4, or amino acid numbers 461 to 996 of SEQ ID NO:
• 6.

A method for treating cancer which is positive for either a fusion gene composed of an FGFR3 gene and a TACC3 gene or a fusion protein composed of FGFR3 and TACC3, comprising administering an effective amount of substance inhibiting the following polypeptide to a subject,

• A polypeptide which has tumorigenicity and comprises an amino acid sequence having 90% or more identity to the amino acid sequence represented by amino acid numbers 461 to 947 of SEQ ID NO:
• 2, amino acid numbers 461 to 982 of SEQ ID NO:
• 4, or amino acid numbers 461 to 996 of SEQ ID NO:
• 6.